Compare DNA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNA | MTLS |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 431.6M |
| IPO Year | 2020 | 2014 |
| Metric | DNA | MTLS |
|---|---|---|
| Price | $7.84 | $7.71 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 142.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $170,155,000.00 | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.37 | $4.78 |
| 52 Week High | $17.58 | $7.72 |
| Indicator | DNA | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 66.20 |
| Support Level | $6.38 | $6.37 |
| Resistance Level | $7.70 | N/A |
| Average True Range (ATR) | 0.33 | 0.27 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 70.33 | 95.76 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.